Publication details
Extrakce klozapinu a jeho metabolitů ze suché kapky krve
| Title in English | Extraction of clozapine and its metabolites from dried blood spots |
|---|---|
| Authors | |
| Year of publication | 2025 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Attached files | |
| Description | Clozapine is an atypical antipsychotic drug indicated for the treatment of resistant schizophrenia. Its dose is adjusted gradually to minimize adverse effects. Plasma concentrations of clozapine show relatively significant interindividual and intraindividual variability. Adherence to treatment is a critical aspect of schizophrenia management, as low adherence leads to low effectiveness. Therapeutic monitoring of treatment is also recommended due to the narrow therapeutic range and limited toxic effects of the drug. Currently, it is performed from plasma, which requires the collection of approximately 5 ml of whole blood. An important part of the analytical process is sample processing before the analysis itself (most often LC-MS today). In the case of a dry blood drop, this involves the release of the analyte from the matrix, extraction and possible further purification/simplification of the sample matrix before separation. The aim of this project was to determine the effect of collecting device material (two types of collection cards and one polymer matrix), the effect of wetting, the composition of the extraction mixture and the extraction time on the extraction efficiency of clozapine and its metabolites – N-desmethylclozapine and clozapine-N-oxide. After optimization, the LC-MS method was validated in basic parameters. Clozapine and its metabolite concentrations determined in DBS will be prospectively correlated with concentrations determined in plasma in real patients. |
| Related projects: |